Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis
1997

Combining Tamoxifen and Docetaxel to Fight Cancer

publication Evidence: moderate

Author Information

Author(s): C Ferlini, G Scambia, M Distefano, P Filippini, G Isola, A Riva, E Bombardelli, A Fattorossi, P Benedetti Panicil, S Mancuso

Primary Institution: Catholic University of Sacred Heart, Rome

Hypothesis

Can the combination of tamoxifen and docetaxel enhance the antiproliferative effects on estrogen receptor-negative cancer cell lines?

Conclusion

The combination of tamoxifen and docetaxel significantly enhances growth inhibition in estrogen receptor-negative cancer cell lines through apoptosis induction.

Supporting Evidence

  • The combination of tamoxifen and docetaxel was more effective in inhibiting growth than either drug alone.
  • Isobolic analysis confirmed the presence of synergism in all tested cell lines.
  • Tamoxifen increased the G/M blocking activity of docetaxel, leading to higher rates of apoptosis.

Takeaway

This study found that using tamoxifen together with docetaxel helps stop cancer cells from growing better than using either drug alone.

Methodology

The study used three estrogen receptor-negative cancer cell lines to test the effects of tamoxifen and docetaxel in combination, analyzing growth inhibition and apoptosis induction.

Limitations

The study was conducted in vitro, and results may not directly translate to in vivo conditions.

Participant Demographics

The study focused on three estrogen receptor-negative cancer cell lines: MDA-MB 231, MCF-7 ADRr, and CEM-VBLr.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication